Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors

Annu Rev Med. 2004;55:355-72. doi: 10.1146/annurev.med.55.091902.104344.

Abstract

An increasing body of evidence suggests that a vaccine that elicits anti-HIV-1 cellular immunity could provide the basis for an effective AIDS vaccine. Comparative immunization experiments testing a variety of vaccine approaches have demonstrated that replication-incompetent adenovirus vectors are an effective means for eliciting cytotoxic T-lymphocyte (CTL) immune responses against HIV-1 antigens. These immune responses effectively control viremia in nonhuman primates following challenge with simian AIDS viruses. Such data, coupled with epidemiology studies that identify HIV-1 gag, pol, and nef as the best antigens for broadly directed cellular immune responses, provide guidance for the development of a potential AIDS vaccine.

Publication types

  • Review

MeSH terms

  • AIDS Vaccines / genetics
  • AIDS Vaccines / therapeutic use*
  • Adenoviridae / physiology*
  • Animals
  • Genetic Vectors / genetics
  • Genetic Vectors / therapeutic use*
  • HIV Infections / prevention & control*
  • HIV-1 / immunology*
  • Humans
  • Virus Replication*

Substances

  • AIDS Vaccines